Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Nevzat TemurokFanny LeonElena PinchonMartine ClotVincent FoulongneJean-François CantaloubePhilippe van de PerreChantal Fournier-WirthJean-Pierre MolesAurélien Daynès
• Organismes : HORIBA Medical Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections HORIBA Medical Pathogenesis and Control of Chronic and Emerging Infections Centre Hospitalier Régional Universitaire [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections Centre Hospitalier Régional Universitaire [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections HORIBA Medical
• Publié dans Talanta le 01/11/2020

---

Résumé : Recent virus outbreaks have revealed a critical need for large scale serological assays. However, many available tests either require a cumbersome, costly apparatus or lack the availability of full automation. In order to address these limitations, we describe a homogeneous assay for antibody detection via measurement of superparamagnetic particles agglutination. Application of a magnetic field permits to overcome the limitations governed by Brownian translational diffusion in conventional assays and results in an important acceleration of the aggregation process as well as an improvement of the limit of detection. Furthermore, the use of protein-concentrated fluid such as 5 times-diluted human plasma does not impair the performances of the method. Screening of human plasma samples shows a strict discrimination between seropositive and seronegative samples in an assay duration as short as 14 s. The sensitivity of this method, combined with its quickness and simplicity, makes it a promising diagnostic tool.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Mohammad AnadaniGaultier MarnatArturo ConsoliPanagiotis PapanagiotouRaul NogueiraAlejandro SpiottaRomain BourcierMaéva KyhengJulien LabreucheAdnan SiddiquiMarc RiboAdam de HavenonUrs FischerIgor SibonCyril DargazanliCaroline ArquizanChristophe CognardJean Marc OlivotRené AnxionnatGérard AudibertMikael MazighiRaphaël BlancBertrand LapergueSébastien RichardBenjamin GoryFrancis TurjmanMichel P. PiotinHenrik Steglich-ArnholmMarkus HoltmannspötterChristian TaschnerSebastian EidenDiogo C. HaussenWaqas MuhammadMaria BoutchakovaFranziska DornMonika Killer-OberpfalzerSalvatore MangiaficoMarios-Nikos PsychogiosMarc-Antoine LabeyrieAlessandra BiondiSerge BracardJonathan Andrew GrossbergAdrien GuenegoJulien DarcourtIsabelle VukasinovicElisa PomeroJason DaviesLeonardo RenieriCorentin HeckerMaria Muchada MuchadaGeorges RodeschEmmanuel HoudartJohanna LockauAndreas KastrupHocine RedjemDaniel BehmeHussain ShallwaniMaurer ChristopherGioia MioneLisa HumbertjeanNolwenn Riou-ComteFrançois ZhuAnne-Laure BorderelleLiang LiaoSimon EscalardJean-Philippes DesillesGabriele CiccioStanislas SmajdaMikael ObadiaCandice SabbenOvide CorabianuThomas de BrouckerDidier SmadjaSonia AlamowitchOlivier IlleÉric ManchonPierre-Yves GarciaGuillaume TaylorMalek Ben MaachaAdrien WangS. EvrardMaya TchikviladzeNadia AjiliDavid WeisenburgerLucas GorzaOguzhan CoskunFederico Di MariaGeorges RodeshMorgan LeguenJulie GratieuxFernando PicoHaja RakotoharinandrasanaPhilippe TassanRoxanna PollSylvie MarinierFlorent GarielXavier BarreauJérôme BergeLouis VeunacPatrice MenegonLudovic LucasStéphane OlindoPauline RenouSharmila SagnierMathilde PoliSabrina DebruxellesThomas TourdiasJean-Sébastien LiegeyBenjamin Daumas-DuportPierre-Louis AlexandreMonica RoyCédric LenobleVincent L'AllinecJean-Baptiste GirotHubert DesalMarc BraunAnne-Laure DerelleRomain TonneletEmmanuelle SchmittSophie PlanelJean-Christophe LacourGabriela HossuMarine BeaumontMitchelle BailangMarie ReitterAgnès MassonLionel AlbAdriana TabarnaMarcela VoicuIona PodarMadalina BrezeanuVincent CostalatGregory GascouPierre-Henri LefevreImad DerrazCarlos RiquelmeNicolas GaillardIsabelle MourandLucas Corti
• Organismes : Washington University School of Medicine in St. Louis Medical University of South Carolina [Charleston] Département de Neuro-Radiologie [Bordeaux] Service Neuroradiologie diagnostique et interventionnelle [Hôpital Foch] National and Kapodistrian University of Athens Emory University School of Medicine Medical University of South Carolina [Charleston] Nantes Université - pôle Santé Evaluation des technologies de santé et des pratiques médicales - ULR 2694 Evaluation des technologies de santé et des pratiques médicales - ULR 2694 University at Buffalo [SUNY] Vall d'Hebron University Hospital [Barcelona] University of Utah Inselspital Bern Service de neurologie [Bordeaux] Neuroradiologie [Hôpital Gui de Chauliac] Neurochirurgie [Hôpital Gui de Chauliac] Service Neuroradiologie Diagnostique et Thérapeutique [CHU Toulouse] Centre Hospitalier Universitaire de Toulouse Département de Neurologie [Toulouse] Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy] Imagerie Adaptative Diagnostique et Interventionnelle Centre Hospitalier Régional Universitaire de Nancy CHU Rothschild [AP-HP] CHU Rothschild [AP-HP] Hôpital Foch [Suresnes] UFR Sciences de la santé Simone Veil Service de neurologie [CHRU Nancy] Imagerie Adaptative Diagnostique et Interventionnelle Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy] Centre Hospitalier Régional Universitaire [Montpellier] Institut de Génomique Fonctionnelle
• Publié dans Journal of Neurointerventional Surgery le 26/10/2020

---

Résumé : Background Endovascular therapy (EVT) is effective and safe in patients with tandem occlusion. The benefit of intravenous thrombolysis (IVT) prior to EVT in acute tandem occlusion is debatable. Objective To compare EVT alone with EVT plus IVT in patients with acute ischemic stroke due to anterior circulation tandem occlusions. Methods This is an individual patient pooled analysis of the Thrombectomy In TANdem lesions (TITAN) and Endovascular Treatment in Ischemic Stroke (ETIS) Registries. Patients were divided into two groups based on prior IVT treatment: (1) IVT+ group, which included patients who received IVT prior to EVT, (2) IVT− group, which included patients who did not receive IVT prior to EVT. Propensity score (inverse probability of treatment weighting (IPTW)) was used to reduce baseline between-group differences. The primary outcome was favorable outcome—that is, modified Rankin Scale (mRS) score 0 to 2 at 90 days. Results Overall, 602 consecutive patients with an acute stroke with tandem occlusion were included (380 and 222 in the bridging therapy and EVT alone groups, respectively). Onset to imaging time was shorter in the IVT+ group (median 103 vs 140 min). In contrast, imaging to puncture time was longer in the IVT+ group (median 107 vs 91 min). In IPTW analysis, the IVT+ group had higher odds of favorable outcome, excellent outcome (90-day mRS score 0–1), and successful reperfusion (modified Thrombolysis in Cerebral Infarction score 2b/3 at the end of EVT). There was no difference in the risk of significant hemorrhagic complications between groups. In secondary analysis of patients treated with acute cervical internal carotid artery stenting, bridging therapy was associated with higher odds of favorable outcome and lower odds of mortality at 90 days. Conclusions Our results suggest that bridging therapy in patients with acute ischemic stroke due to anterior tandem occlusion is safe and may improve functional outcome, even in the setting of acute cervical internal carotid artery stenting during EVT.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Xiangzhuo LiuWigneron J.-P.Sassan S SaatchiFrédéric FrappartPhilippe CiaisNicolas BaghdadiMehrez ZribiThomas JagdhuberXiaojun LiMengjia WangXiaojing BaiChristophe Moisy
• Organismes : Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère Chongqing University [Chongqing] Interactions Sol Plante Atmosphère Laboratoire d'études en Géophysique et océanographie spatiales Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Territoires, Environnement, Télédétection et Information Spatiale Centre d'études spatiales de la biosphère German Aerospace Center Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère Beijing Normal University Nanjing University Interactions Sol Plante Atmosphère
• Publié dans Remote Sensing of Environment le 28/10/2020

---

Résumé : Vegetation optical depth (VOD), as a microwave-based vegetation index for vegetation water and biomass content, is increasingly used to study the impact of global climate and environmental changes on vegetation. Currently, VOD is mainly retrieved from passive microwave data and few studies focused on VOD retrievals from active microwave data. The Advanced SCATterometer (ASCAT) provides long-term C-band backscatter data at Vertical-Vertical (VV) polarization. In this study, a new ASCAT INRAE Bordeaux (IB) VOD (hereafter, IB VOD), was developed based on the Water Cloud Model (WCM) coupled with the Ulaby linear model for soil backscattering. The main features of IB VOD are that (i) the ERA5-Land soil moisture (SM) dataset was used as an auxiliary SM dataset in the retrievals, (ii) pixel-based soil model parameters were mapped using Random Forest (RF), and (iii) the vegetation model parameter was calibrated for each day. The IB VOD product was retrieved over Africa during 2015–2019, and its performances were evaluated in space and time by comparing with aboveground biomass (AGB), lidar tree height (TH), normalized difference vegetation index (NDVI), enhanced vegetation index (EVI) and leaf area index (LAI). Results were inter-compared with three other VOD products at the same frequency. In terms of spatial correlation with AGB (R = 0.92) and TH (R = 0.89), IB VOD outperforms the other VOD products, suggesting IB VOD has a strong ability to capture spatial patterns of AGB and TH. By comparing all VOD products against NDVI, EVI and LAI, we found that the highest temporal correlation with NDVI (EVI, LAI) was obtained with IB VOD over 29.94% (36.65%, 30.19%) of the study region. Considering all three vegetations indices, highest temporal correlation values with IB VOD could be particularly noted for deciduous broadleaf forests, woody savannas and savannas.

---

Fichiers liés : S0034425721003072.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Gerhard HindricksTatjana PotparaNikolaos DagresElena ArbeloJeroen BaxCarina Blomström-LundqvistGiuseppe BorianiManuel CastellaGheorghe-Andrei DanPolychronis DilaverisLaurent FauchierGerasimos FilippatosJonathan KalmanMark La MeirDeirdre LaneJean-Pierre LebeauMaddalena LettinoDavid FitzmauriceFausto PintoG Neil ThomasMarco ValgimigliIsabelle van GelderBart van PutteCaroline WatkinsJohannes BrachmannMichael KühneVictor AboyansAnders AhlssonPawel BalsamJohann BauersachsStefano BenussiAxel BrandesFrieder Braunschweiga John CammDavide CapodannoBarbara CasadeiDavid ConenHarry CrijnsVictoria DelgadoDobromir DobrevHeinz DrexelLars EckardtDonna FitzsimonsThierry FolliguetChris GaleBulent GorenekKarl Georg HaeuslerHein HeidbuchelBernard IungHugo KatusDipak KotechaUlf LandmesserChristophe LeclercqBasil LewisJulia MascherbauerJose Luis MerinoBéla MerkelyLluís MontChristian MuellerKlaudia NagyJonas OldgrenNikola PavlovićRoberto PedrettiSteffen PetersenJonathan PicciniBogdan PopescuHelmut PürerfellnerDimitrios RichterMarco RoffiAndrea RubboliDaniel ScherrRenate SchnabelIain SimpsonEvgeny ShlyakhtoMoritz SinnerJan SteffelMiguel Sousa-UvaPiotr SuwalskiMartin SvetlosakRhian TouyzG Neil ThomasTahar DelassiHamayak SisakianAlexandr ChasnoitsMichel De PauwElnur SmajićTchavdar ShalganovPanayiotis AvraamidesJosef KautznerChristian GerdesAhmad Abd AlazizPriit KampusPekka RaatikainenSerge BovedaGiorgi PapiashviliVassilios VassilikosZoltán CsanádiDavid ArnarJoseph GalvinAlon BarsheshetPasquale CaldarolaAmina RakishevaIbadete BytyçiAlina KerimkulovaOskars KalejsMario NjeimAras PuodziukynasLaurent GrobenMark SammutAurel GrosuAneta BoskovicAbdelhamid MoustaghfirNatasja De GrootLidija PoposkaOle-Gunnar AnfinsenPrzemyslaw MitkowskiDiogo Magalhães CavacoCalin SilisteEvgeny MikhaylovLuca BertelliDejan KojicRobert HatalaZlatko FrasFernando ArribasTord JuhlinChristian SticherlingLeila AbidIlyas AtarOleg SychovMatthew BatesNodir ZakirovJean-Michel HalimiPhilippe GataultHélène LonguetChristelle BarbetAnnabelle GoumardJuliette GueguenNicolas GoinBenedicte SautenetJulien HerbertArnaud Bisson
• Organismes : Leipzig University / Universität Leipzig University of Belgrade [Belgrade] Leipzig University / Universität Leipzig Leiden University Medical Center [Leiden] Uppsala University Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia Spitalul Clinic Colentina = Colentina Hospital [Bucharest, Romania] University of Medicine and Pharmacy “Carol Davila” CHU Trousseau [Tours] Éducation Éthique Santé National and Kapodistrian University of Athens Université d'Athènes “Attikon” University Hospital The Royal Melbourne Hospital University of Liverpool Éducation Éthique Santé San Gerardo Hospital Company Monza University of Liverpool Aalborg University Universidade Nova de Lisboa = NOVA University Lisbon Faculdade de Medicina [Lisboa] Hospital de Santa Maria [Lisboa] CHU Trousseau [Tours] Service de néphrologie et immunologie clinique [CHRU Tours] CHU Trousseau [Tours] CHU Trousseau [Tours] CHU Trousseau [Tours] Centre de recherche en épidémiologie et santé des populations methodS in Patients-centered outcomes and HEalth ResEarch Service de néphrologie et immunologie clinique [CHRU Tours] CHU Trousseau [Tours] CHU Trousseau [Tours]
• Publié dans Kidney International Reports le 26/10/2020

---

Fichiers liés : main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Helena DegrooteFederico PiñeroCharlotte CostentinAndrea NotarpaoloIlka F BoinKarim BoudjemaCinzia BaccaroAline Lopes ChagasPhilippe BachellierGiuseppe Maria EttorreJaime PoniachikFabrice MuscariFabrio Di BenedettoSergio Hoyos DuqueÉphrem SalameUmberto CilloAdrián GadanoClaire VanlemmensStefano FagiuoliFernando RubinsteinPatrizia BurraDaniel CherquiMarcelo SilvaHans van VlierbergheChristophe DuvouxFilomena ContiOlivier ScattonPierre-Henri BernardClaire FrancozFrançois DurandSebastien DharancyMarie-Lorraine WoehlAlexis LaurentSylvie RadenneJérôme DumortierArmand AbergelLouise BarbierPauline Houssel-DebryGeorges-Philippe PageauxLaurence ChicheVictor DeledinghenJean HardwigsenJ. GugenheimM. AltieriMarie-Noëlle HilleretThomas DecaensAline ChagasPaulo S CostaElaine Cristina de AtaideEmilio QuiñonesSebastian MarcianoMargarita AndersAdriana VarónAlina ZeregaAlejandro SozaMartín Padilla-MachacaDiego ArufeJosemaría MenéndezRodrigo ZapataMario VilatobaLinda MuñozRicardo Chong-MenéndezMartín MaraschioLuis G PodestáMartin FaudaA. Gonzalez-CampañaLucas MccormackJuan MatteraIlka Sf Fatima BoinJose Huygens Parente GarcíaFlair CarrilhoGiulia MaginiLucia MiglioresiMartina GambatoFabrizio DibenedettoCecilia d'AmbrosioAlessandro VitaleMichele ColledanDomenico PinelliPaolo MagistriGiovanni VennarecciMarco ColasantiValerio GiannelliAdriano PellicelliCizia BaccaroCallebout EduardIesari SamueleDekervel JeroenJonas SchreiberJacques PirenneChris VerslypeDirk YsebaertPeter MichielsenValerio LucidiChristophe MorenoOlivier DetryJean DelwaideRoberto TroisiJan-Paul Lerut
• Organismes : Ghent University Hospital Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) Centre Hospitalier Universitaire [CHU Grenoble] Arcispedale S Maria Nuova Universidade Estadual de Campinas = University of Campinas Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Université de Rennes Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Universitaire de Toulouse Universidad de Antioquia = University of Antioquia [Medellín, Colombia] CHU Trousseau [Tours] Centre Hospitalier Régional Universitaire de Besançon Hospital Papa Giovanni XXIII Ghent University Hospital Service d'hépato-gastro-entérologie [APHP Henri Mondor] Centre Hospitalier Régional Universitaire [Montpellier] Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB)
• Publié dans JHEP Reports Innovation in Hepatology le 07/09/2020

---

Résumé : BACKGROUND and AIMS: Good outcomes after liver transplantation (LT) have been reported after successfully downstaging to Milan criteria in more advanced hepatocellular carcinoma (HCC). We aimed to compare post-LT outcomes in patients receiving locoregional therapies (LRT) before LT according to Milan criteria and University of California San Francisco downstaging (UCSF-DS) protocol and ’all-comers’. METHODS: This multicentre cohort study included patients who received any LRT before LT from Europe and Latin America (2000-2018). We excluded patients with alpha-foetoprotein (AFP) above 1,000 ng/ml. Competing risk regression analysis for HCC recurrence was conducted, estimating subdistribution hazard ratios (SHRs) and corresponding 95% CIs. RESULTS: From 2,441 LT patients, 70.1% received LRT before LT (n = 1,711). Of these, 80.6% were within Milan, 12.0% within UCSF-DS, and 7.4% all-comers. Successful downstaging was achieved in 45.2% (CI 34.8-55.8) and 38.2% (CI 25.4-52.3) of the UCSF-DS group and all-comers, respectively. The risk of recurrence was higher for all-comers (SHR 6.01 [p <0.0001]) and not significantly higher for the UCSF-DS group (SHR 1.60 [p = 0.32]), compared with patients remaining within Milan. The all-comers presented more frequent features of aggressive HCC and higher tumour burden at explant. Among the UCSF-DS group, an AFP value of ≤20 ng/ml at listing was associated with lower recurrence (SHR 2.01 [p = 0.006]) and better survival. However, recurrence was still significantly high irrespective of AFP ≤20 ng/ml in all-comers. CONCLUSIONS: Patients within the UCSF-DS protocol at listing have similar post-transplant outcomes compared with those within Milan when successfully downstaged. Meanwhile, all-comers have a higher recurrence and inferior survival irrespective of response to LRT. Additionally, in the UCSF-DS group, an ALP of ≤20 ng/ml might be a novel tool to optimise selection of candidates for LT. CLINICAL TRIAL NUMBER: This study was registered as part of an open public registry (NCT03775863). LAY SUMMARY: Patients with more extended HCC (within the UCSF-DS protocol) successfully downstaged to the conventional Milan criteria do not have a higher recurrence rate after LT compared with the group remaining in the Milan criteria from listing to transplantation. Moreover, in the UCSF-DS patient group, an ALP value equal to or below 20 ng/ml at listing might be a novel tool to further optimise selection of candidates for LT.

---

Fichiers liés : Degroote-2021-International study on the outcome of locoregional therapy.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Pierre-Jean LartaudDavid HalléArnaud SchleefRiham DessoukyAnna Sesilia VlachomitrouPhilippe DouekJean-Michel RouetOlivier NempontL. Boussel
• Organismes : Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Modeling & analysis for medical imaging and Diagnosis Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Modeling & analysis for medical imaging and Diagnosis
• Publié dans International Journal of Computer Assisted Radiology and Surgery le 30/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Lise BertinAnthony CanellasBaptiste AbbarMarianne VeyriJean-Philippe SpanoJacques CadranelArmelle Lavolé
• Organismes : CHU Tenon [AP-HP] Groupe de recherche clinique Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules Groupe de recherche clinique Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules CHU Tenon [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut Universitaire de Cancérologie [Sorbonne Université] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Universitaire de Cancérologie [Sorbonne Université] Institut Universitaire de Cancérologie [Sorbonne Université] CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Tenon [AP-HP] Groupe de recherche clinique Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules CHU Tenon [AP-HP] Groupe de recherche clinique Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules
• Publié dans JTO Clinical and Research Reports le 07/10/2021

---

Résumé : In the recent past, we observed an increased risk of cancer in the HIV population due to the development of antiretroviral therapies that decreased mortality caused by HIV-specific infections. This particularly fragile population is frequently excluded from clinical trials, and up-to-date recommendations for these patients are lacking. Only few cases of HIV patients suffering from cancer and undergoing first-line immunotherapy have been reported so far. Here we report the largest known study of HIV patients with non-small cell lung cancer (NSCLC) (5 patients) undergoing first-line immunotherapy by pembrolizumab, following CANCERVIH group selection. Our results are consistent with previous case reports concerning safety of immunotherapy in HIV patients, showing no severe or fatal toxicity, opportunistic infections, or immune reconstitution inflammatory syndrome (IRIS). Moreover, pembrolizumab did not seem to modify HIV viral parameters. We also assessed effectiveness of immunotherapy in these HIV-immunosuppressed patients: the average survival was 9.8 months, with three patients showing rapid progression and two partial response. However, as well as safety and drug-to-drug interactions, the effectiveness of first-line immunotherapy in people living with HIV (PLWHIV) needs to be supported by larger studies.

---

Fichiers liés : 1-s2.0-S2666364321001065-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Clément DuboisFrederiek NuytensHélène BehalCaroline GronnierGilles ManceauMaxime WarlaumontAlain DuhamelQuentin DenostCharles HonoréOlivier FacyJean-Jacques TuechGuido TiberioCécile BrigandJean-Pierre BailEphrem SalaméBernard MeunierJérémie LefevreMuriel MathonnetMohamed Sbai IdrissiFlorence RenaudGuillaume PiessenFrançois BrowetCharles SabbaghJean-Marc RégimbeauEmilie LermiteAntoine HamyKevin KraftRichard DouardPhilippe WindHélène Gersen-CherdieuDenis ColletMagalie CabauChristophe LaurentEric RullierArianna ConiglioCharles-Henry GancelBogdan BadicGilbert OuedraogoMircea BeuranAude BramsMarc KanorChristophe LouisYves RussierYves PanisLéon MaggioriCamille CailleGéraud TuyerasSimon MsikaLuigi de MagistrisT. PerrinPatrick RatPablo Ortega DeballonPhilippe MeignieJean François BronnerJacques MolineClaude MondersertAndré CaamanoCatherine ArvieuxJean-Luc FaucheronChristian LetoublonAntoine GuillaudSégolène LardenoisJean-Michel NussPatrick ChevillotteEdouard VinatierWilliams TessierRobert CaiazzoFrançois PattouNicolas LamandeMehrdad JafariGauthier DecanterFrançois ParafMohamed AlyamiDelphine VaudoyerGuillaume PassotOlivier GlehenHassan DemianChristian DucerfJean-Yves MabrutMarc RivoireVincent GarbitThierry LeclercqJean LoireOlivier RaspadoRémy Le Huu NhoMehdi OuaïssiIgor SieleznefBernard SastreBernard PolManuela CampanileSami HamedJean HardwigsenYves-Patrice Le TreutGérard CarbonnelCharlotte de Saint RomanM. TréotPhilippe SockeelGhislain TourreauVasileios BaltzopoulosAnne MourregotPhilippe RouanetL. BreslerP. SenellartGuillaume MeurettePaul Antoine LehurNicolas RegenetVincent CasanovaAnne Sophie SchneckAntonio IanelliJean GugenheimMehdi KarouiJean Christophe VaillantJean Baptise BachetLaurent HannounRenato LupinacciFrancois MenegauxChristophe TresalletAntoine BrouquetStéphane BenoistChristophe PennaPierre BalladurYann ParcFrançois PayeNajim ChafaiEmmanuel TiretPierre CattanEmile SarfatiLeonor BenhaimF. SistaSidney HouryPascale MarianiBéatrice Ullua SeverinoBrice GayetThierry PerniceniJean-Pierre RicherJean-Pierre FaureJean Louis KraimpsSophie Deguelte-LardiereOlivier BoucheReza KianmaneschCharles Le Clec’hLaurent SulpiceBernard MeunierKarim BoudjemaEmmanuel HuetMichel ScotteFrancis MichotThomas SoleClément CostanzaCharlotte VermeschSantina BrunoJack PorcheronM. RaharimanantsoaPatrick PessauxSilvana PerrettaDidier MutterH. MercoliA. KlipfelE. TrikiB. RomainS. DragomirN. ChilintsevaJ. OlliernSerge RohrAlexandre RaultCharles Henri JulioMael Chalret Du RieuNicolas CarrèreBernard PradèrePerrine SenellartBaudoin ThébaultNicolo de ManziniChristophe HenrySylvie Bonvalot
• Organismes : Evaluation des technologies de santé et des pratiques médicales - ULR 2694 Evaluation des technologies de santé et des pratiques médicales - ULR 2694 Interface de Recherche Fondamentale et Appliquée en Cancérologie Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277
• Publié dans Annals of Surgical Oncology le 26/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2021
• Auteurs : Djillali AnnaneMartin RottmanNicholas HemingVéronique GodotJérôme FleurietJean Sébastien BlanchetPierre MoineLamiae GrimaldiSylvie ChevretAnnane DjillaliMoine PierreHeming NicholasMaxime VirginieClair BernardOrlikowski DavidBouneb RaniaMurg EleonoraAbdeladim LiliaFayssoil AbdallahBlanchet Jean-SébastienChevret SylvieDaniel ChristelDevillier PhilippeFleuriet JéromeFrançois BrunoGarchon Henri-JeanGodot VéroniqueGrassin-Delyle StanislasGrimaldi LamiaeKedad ZoubidaLassalle PhilippeU. Richly MaximilianRottman MartinRoux Anne-LaureTalini LucZeitouni KarineDjillali AnnaneValérie BardetXavier MonnetLamiae GrimaldiSylvie ChevretAnne-Laure RouxMartin RottmanStanislas Grassin DelyleHenri-Jean GarchonXavier MonnetAntoine Vieillard-BaronGuillaume GériZiad MassyJean-Claude AlvarezMarie EssigAmine LarabiValérie BardetBruno MégarbaneNicholas HemingPierre TissièresFrançois FayMarie-Anne Rameix-WeltiBruno MégarbanePierre MoineKarine ZeitouniLaurent DumasZaineb ChellyMartin RottmanAnne-Laure RouxLoïc JosseranMahmoud Zureik
• Organismes : Optimisation thérapeutique en Neuropsychopharmacologie
• Publié dans Intensive Care Medicine le 27/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 30/09/2021
• Auteurs : Paul PlatzerPascal YiouPhilippe NaveauJean-François FilipotMaxime ThiébautPierre Tandeo
• Organismes : France Énergies Marines [Brest] Département Mathematical and Electrical Engineering Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance Extrèmes : Statistiques, Impacts et Régionalisation Extrèmes : Statistiques, Impacts et Régionalisation France Énergies Marines [Brest] France Énergies Marines [Brest] Département Mathematical and Electrical Engineering Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance
• Publié dans Journal of the Atmospheric Sciences le 30/10/2020

---

Résumé : Some properties of chaotic dynamical systems can be probed through features of recurrences, also called analogs. In practice, analogs are nearest neighbours of the state of a system, taken from a large database called the catalog. Analogs have been used in many atmospheric applications including forecasts, downscaling, predictability estimation, and attribution of extreme events. The distances of the analogs to the target state condition the performances of analog applications. These distances can be viewed as random variables, and their probability distributions can be related to the catalog size and properties of the system at stake. A few studies have focused on the first moments of return time statistics for the best analog, fixing an objective of maximum distance from this analog to the target state. However, for practical use and to reduce estimation variance, applications usually require not just one, but many analogs. In this paper, we evaluate from a theoretical standpoint and with numerical experiments the probability distributions of the $K$-best analog-to-target distances. We show that dimensionality plays a role on the size of the catalog needed to find good analogs, and also on the relative means and variances of the $K$-best analogs. Our results are based on recently developed tools from dynamical systems theory. These findings are illustrated with numerical simulations of a well-known chaotic dynamical system and on 10m-wind reanalysis data in north-west France. A practical application of our derivations for the purpose of objective-based dimension reduction is shown using the same reanalysis data.

---

Fichiers liés : Analog_Distances_Distributions__JAS_nolineno_compressed.pdf

---

Source